Evaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients: A randomized clinical trial study

Zahedan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2020年10月6日

试验速览

暂无简介。

•Subjects with COVID-19 in the second phase of the disease
•Shortness of breath, chest pain with or without fever equal to or greater than 38 'C
•Blood oxygen saturation (SpO2) between 90-93%
•Adult patients with COVID-19 with moderate pulmonary involvement and hospitalized in the general ward who have been diagnosed and confirmed with coronavirus by conventional diagnostic methods such as sequencing or qRT-PCR and CT (within 48 hours of admission)
•Age range of patients between 18-65 years
•Existence of pneumonia in lung CT scan with involvement of maximum 3 or 4 lung lobes or less than one third of the volume of each lobe or infection of one or two lobes with larger area
•Patients informed consent

•Patients under 18 or over 65 years old
•Patients with severe and advanced disease are admitted to the intensive care unit
•Participate in another clinical trial
•Shock and critical illness (requires ventilator and organ failure)
•Patients with organ dysfunction such as renal failure and liver damage, patients with asthma
•Taking certain medications such as furosemide or Lasex, lithium, ACE2 inhibitors
•People with medical history such as high blood pressure, autoimmune diseases and ..

发起方

Zahedan University of Medical Sciences